# CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.

> **NCT03614858** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd** · enrollment: 20 (estimated)

## Conditions studied

- Leukemia, B-cell

## Interventions

- **BIOLOGICAL:** CART-19/22

## Key facts

- **NCT ID:** NCT03614858
- **Lead sponsor:** Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-09-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-11-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03614858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03614858, "CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03614858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*